Advertisement
Canada markets close in 6 hours 30 minutes

  • S&P/TSX

    21,694.21
    -20.33 (-0.09%)
     

  • S&P 500

    5,030.52
    -5.17 (-0.10%)
     

  • DOW

    37,858.71
    +42.79 (+0.11%)
     

  • CAD/USD

    0.7267
    +0.0006 (+0.09%)
     

  • CRUDE OIL

    80.71
    -1.22 (-1.49%)
     

  • Bitcoin CAD

    79,344.84
    -4,822.35 (-5.73%)
     

  • CMC Crypto 200

    1,203.65
    -135.41 (-10.11%)
     

  • GOLD FUTURES

    2,310.00
    +7.10 (+0.31%)
     

  • RUSSELL 2000

    1,973.91
    -42.12 (-2.09%)
     

  • 10-Yr Bond

    4.6550
    -0.0310 (-0.66%)
     

  • NASDAQ

    15,654.96
    -2.86 (-0.02%)
     

  • VOLATILITY

    16.02
    +0.37 (+2.36%)
     

  • FTSE

    8,142.22
    -1.91 (-0.02%)
     

  • NIKKEI 225

    38,274.05
    -131.61 (-0.34%)
     

  • CAD/EUR

    0.6802
    0.0000 (0.00%)
     
MARKETS LIVE BLOG:

S&P 500 FUTURES SLIDE WITH FED'S POWELL IN SPOTLIGHT

U.S. central bank widely expected to keep rates at 23-year high later Wednesday

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

PR Newswire
·2 min read

NEW YORK, April 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that Lucid's President & Chief Operating Officer Shaun O'Neil will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 11:00 a.m. E.T.

Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)
Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)

The fireside chat will be webcast live and can be accessed by visiting the Investor Relations Section of the Lucid Diagnostics website or by clicking here.  A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast. Company management will meet with investors in one-on-one meetings during the conference.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool for at-risk patients to mitigate the risks of cancer and cancer deaths through early detection of esophageal precancer.

ADVERTISEMENT

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

 

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-fireside-chat-at-the-23rd-annual-needham-virtual-healthcare-conference-302110087.html

SOURCE Lucid Diagnostics